Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Drug companies 'not happy' that drug prices 'are going down,' Trump tweets » 10:00
08/13/20
08/13
10:00
08/13/20
10:00
JNJ

Johnson & Johnson

$148.16 /

-1.5 (-1.00%)

, LLY

Eli Lilly

$151.07 /

-0.04 (-0.03%)

, MRK

Merck

$82.53 /

-0.19 (-0.23%)

, PFE

Pfizer

$38.03 /

-0.31 (-0.81%)

, SNY

Sanofi

$51.33 /

-0.55 (-1.06%)

, AZN

AstraZeneca

$56.22 /

+0.37 (+0.66%)

, GSK

GlaxoSmithKline

$41.37 /

+0.1878 (+0.46%)

, NVS

Novartis

$85.50 /

+0.575 (+0.68%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$63.19 /

-0.44 (-0.69%)

President Donald Trump…

President Donald Trump tweeted: "Drug companies, which are being forced by me to substantially reduce Drug Prices, are taking $millions in ads saying I want to increase Medicare Primiums. Wrong, just the opposite! These ads show DRUG PRICES ARE GOING DOWN, and they are not happy! False advertising!" Large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Reference Link

ShowHide Related Items >><<
SNY Sanofi
$51.33 /

-0.55 (-1.06%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.03 /

-0.31 (-0.81%)

NVS Novartis
$85.50 /

+0.575 (+0.68%)

MRK Merck
$82.53 /

-0.19 (-0.23%)

LLY Eli Lilly
$151.07 /

-0.04 (-0.03%)

JNJ Johnson & Johnson
$148.16 /

-1.5 (-1.00%)

GSK GlaxoSmithKline
$41.37 /

+0.1878 (+0.46%)

BMY Bristol-Myers
$63.19 /

-0.44 (-0.69%)

AZN AstraZeneca
$56.22 /

+0.37 (+0.66%)

JNJ Johnson & Johnson
$148.16 /

-1.5 (-1.00%)

07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/29/20 Laidlaw
Curis initiated with a Buy at Laidlaw
07/17/20 Goldman Sachs
J&J valuation discount to S&P 500 'too wide,' says Goldman Sachs
07/17/20 Citi
Johnson & Johnson price target raised to $170 from $165 at Citi
LLY Eli Lilly
$151.07 /

-0.04 (-0.03%)

07/31/20 Barclays
Eli Lilly earnings selloff 'meaningful over-reaction,' says Barclays
07/15/20 H.C. Wainwright
Blueprint Medicines price target raised to $110 from $66 at H.C. Wainwright
07/14/20 Baird
Blueprint Medicines price target raised to $100 from $90 at Baird
07/14/20 Raymond James
Blueprint Medicines price target raised to $106 from $95 at Raymond James
MRK Merck
$82.53 /

-0.19 (-0.23%)

08/11/20 H.C. Wainwright
Pfenex acquisition fits well with Ligand growing portfolio, says H.C. Wainwright
08/04/20 Piper Sandler
Merck deal sparks interest in GLP-1:glucagon agonists, says Piper Sandler
08/03/20
Fly Intel: Top five analyst upgrades
08/03/20 Goldman Sachs
Merck upgraded to Buy from Neutral at Goldman Sachs
PFE Pfizer
$38.03 /

-0.31 (-0.81%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
SNY Sanofi
$51.33 /

-0.55 (-1.06%)

08/10/20 SVB Leerink
Principia Biopharma price target raised to $112 from $80 at SVB Leerink
07/31/20 JPMorgan
Sanofi price target raised to EUR 106 from EUR 103 at JPMorgan
07/20/20 BMO Capital
Immunic initiated with an Outperform at BMO Capital
07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
AZN AstraZeneca
$56.22 /

+0.37 (+0.66%)

07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
GSK GlaxoSmithKline
$41.37 /

+0.1878 (+0.46%)

08/12/20 UBS
GlaxoSmithKline price target lowered to 1,800 GBp from 1,920 GBp at UBS
07/31/20 Barclays
Barclays backs Underweight on GSK after 'challenging' Q2
07/30/20 Roth Capital
Roth Capital bullish on Ideaya as GSK highlights synthetic lethality pipeline
07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
NVS Novartis
$85.50 /

+0.575 (+0.68%)

08/12/20 JPMorgan
Novartis price target lowered to CHF 82 from CHF 84 at JPMorgan
07/28/20 Morgan Stanley
Novartis price target raised to CHF 93 from CHF 91 at Morgan Stanley
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
BMY Bristol-Myers
$63.19 /

-0.44 (-0.69%)

08/06/20 Citi
Investors can refocus on Bristol-Myers story after Eliquis win, says Citi
07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
07/28/20 Raymond James
Bristol-Myers initiated with an Outperform at Raymond James
SNY Sanofi
$51.33 /

-0.55 (-1.06%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.03 /

-0.31 (-0.81%)

NVS Novartis
$85.50 /

+0.575 (+0.68%)

MRK Merck
$82.53 /

-0.19 (-0.23%)

LLY Eli Lilly
$151.07 /

-0.04 (-0.03%)

JNJ Johnson & Johnson
$148.16 /

-1.5 (-1.00%)

GSK GlaxoSmithKline
$41.37 /

+0.1878 (+0.46%)

BMY Bristol-Myers
$63.19 /

-0.44 (-0.69%)

AZN AstraZeneca
$56.22 /

+0.37 (+0.66%)

SNY Sanofi
$51.33 /

-0.55 (-1.06%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.03 /

-0.31 (-0.81%)

NVS Novartis
$85.50 /

+0.575 (+0.68%)

MRK Merck
$82.53 /

-0.19 (-0.23%)

LLY Eli Lilly
$151.07 /

-0.04 (-0.03%)

JNJ Johnson & Johnson
$148.16 /

-1.5 (-1.00%)

GSK GlaxoSmithKline
$41.37 /

+0.1878 (+0.46%)

AZN AstraZeneca
$56.22 /

+0.37 (+0.66%)

SNY Sanofi
$51.33 /

-0.55 (-1.06%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NVS Novartis
$85.50 /

+0.575 (+0.68%)

MRK Merck
$82.53 /

-0.19 (-0.23%)

LLY Eli Lilly
$151.07 /

-0.04 (-0.03%)

JNJ Johnson & Johnson
$148.16 /

-1.5 (-1.00%)

BMY Bristol-Myers
$63.19 /

-0.44 (-0.69%)

AZN AstraZeneca
$56.22 /

+0.37 (+0.66%)

SNY Sanofi
$51.33 /

-0.55 (-1.06%)

PFE Pfizer
$38.03 /

-0.31 (-0.81%)

NVS Novartis
$85.50 /

+0.575 (+0.68%)

MRK Merck
$82.53 /

-0.19 (-0.23%)

LLY Eli Lilly
$151.07 /

-0.04 (-0.03%)

JNJ Johnson & Johnson
$148.16 /

-1.5 (-1.00%)

GSK GlaxoSmithKline
$41.37 /

+0.1878 (+0.46%)

BMY Bristol-Myers
$63.19 /

-0.44 (-0.69%)

AZN AstraZeneca
$56.22 /

+0.37 (+0.66%)

Periodicals
Mexico, Argentina to produce AstraZeneca's COVID-19 vaccine, Bloomberg says » 07:49
08/13/20
08/13
07:49
08/13/20
07:49
AZN

AstraZeneca

$56.30 /

+1.59 (+2.91%)

Mexico and Argentina have…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AZN AstraZeneca
$56.30 /

+1.59 (+2.91%)

AZN AstraZeneca
$56.30 /

+1.59 (+2.91%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
AZN AstraZeneca
$56.30 /

+1.59 (+2.91%)

AZN AstraZeneca
$56.30 /

+1.59 (+2.91%)

AZN AstraZeneca
$56.30 /

+1.59 (+2.91%)

AZN AstraZeneca
$56.30 /

+1.59 (+2.91%)

Hot Stocks
AstraZeneca announces first shipment of Flumist Quadrivalent doses in the U.S. » 07:33
08/13/20
08/13
07:33
08/13/20
07:33
AZN

AstraZeneca

$56.30 /

+1.59 (+2.91%)

AstraZeneca announced the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AZN AstraZeneca
$56.30 /

+1.59 (+2.91%)

AZN AstraZeneca
$56.30 /

+1.59 (+2.91%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
AZN AstraZeneca
$56.30 /

+1.59 (+2.91%)

AZN AstraZeneca
$56.30 /

+1.59 (+2.91%)

AZN AstraZeneca
$56.30 /

+1.59 (+2.91%)

AZN AstraZeneca
$56.30 /

+1.59 (+2.91%)

Yesterday
Conference/Events
Cantor Fitzgerald biopharma analysts to hold analyst/industry conference call » 11:44
08/12/20
08/12
11:44
08/12/20
11:44
PFE

Pfizer

$38.34 /

+0.54 (+1.43%)

, MMA

Municipal Mortgage

$0.00 /

+ (+0.00%)

, AZN

AstraZeneca

$57.12 /

+1.96 (+3.55%)

, LLY

Eli Lilly

$152.02 /

+1.41 (+0.94%)

Large Cap & Biopharma…

Large Cap & Biopharma Analysts Chen & Kim, along with Key Opinion Leader Dr. Robert Kruse, of Johns Hopkins School of Medicine, discuss Pfizer vs Moderna's COVID-19 vaccine, as well as other leading vaccines in development including AstraZeneca, Eli Lilly, Oxford, on an Analyst/Industry conference call to be held on August 18 at 1 pm.

ShowHide Related Items >><<
PFE Pfizer
$38.34 /

+0.54 (+1.43%)

LLY Eli Lilly
$152.02 /

+1.41 (+0.94%)

AZN AstraZeneca
$57.12 /

+1.96 (+3.55%)

PFE Pfizer
$38.34 /

+0.54 (+1.43%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
MMA Municipal Mortgage
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$57.12 /

+1.96 (+3.55%)

07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
LLY Eli Lilly
$152.02 /

+1.41 (+0.94%)

07/31/20 Barclays
Eli Lilly earnings selloff 'meaningful over-reaction,' says Barclays
07/15/20 H.C. Wainwright
Blueprint Medicines price target raised to $110 from $66 at H.C. Wainwright
07/14/20 Baird
Blueprint Medicines price target raised to $100 from $90 at Baird
07/14/20 Raymond James
Blueprint Medicines price target raised to $106 from $95 at Raymond James
PFE Pfizer
$38.34 /

+0.54 (+1.43%)

LLY Eli Lilly
$152.02 /

+1.41 (+0.94%)

AZN AstraZeneca
$57.12 /

+1.96 (+3.55%)

PFE Pfizer
$38.34 /

+0.54 (+1.43%)

LLY Eli Lilly
$152.02 /

+1.41 (+0.94%)

AZN AstraZeneca
$57.12 /

+1.96 (+3.55%)

PFE Pfizer
$38.34 /

+0.54 (+1.43%)

LLY Eli Lilly
$152.02 /

+1.41 (+0.94%)

AZN AstraZeneca
$57.12 /

+1.96 (+3.55%)

PFE Pfizer
$38.34 /

+0.54 (+1.43%)

LLY Eli Lilly
$152.02 /

+1.41 (+0.94%)

AZN AstraZeneca
$57.12 /

+1.96 (+3.55%)

Tuesday
Hot Stocks
FibroGen enrolls first patient in Phase 3 pamrevlumab clinical trial » 07:12
08/11/20
08/11
07:12
08/11/20
07:12
FGEN

FibroGen

$45.10 /

+0.86 (+1.94%)

FibroGen announced the…

FibroGen announced the initiation of LELANTOS, a Phase 3, randomized, double-blind, placebo-controlled trial of pamrevlumab or placebo in combination with systemic corticosteroids in patients with non-ambulatory Duchenne muscular dystrophy. The primary objective of this global study is to evaluate the effect of pamrevlumab on muscle function in patients with DMD. Approximately 90 patients will be randomized 1:1 to receive pamrevlumab plus systemic corticosteroids, or placebo plus systemic corticosteroids, for up to 52 weeks. The primary efficacy endpoint is the change in the total score of performance of upper limb assessment, from baseline to Week 52, and additional endpoints include pulmonary and cardiac function tests. Subjects who complete the 52-week study will be eligible for rollover into an open-label extension study with pamrevlumab and systemic corticosteroids.

ShowHide Related Items >><<
FGEN FibroGen
$45.10 /

+0.86 (+1.94%)

FGEN FibroGen
$45.10 /

+0.86 (+1.94%)

07/10/20 Stifel
FibroGen transferred with Buy rating, $71 target at Stifel
05/06/20 RBC Capital
Akebia price target raised to $12 from $8 at RBC Capital
05/05/20 Piper Sandler
Piper Sandler remains a buyer of Akebia following Phase 3 INNO2VATE data
05/05/20 Piper Sandler
Piper says efficacy, safety of FibroGen, Akebia drugs 'quite similar' in DD-CKD
FGEN FibroGen
$45.10 /

+0.86 (+1.94%)

FGEN FibroGen
$45.10 /

+0.86 (+1.94%)

Hot Stocks
Bicycle Therapeutics appoints Dominc Smethurst as Chief Medical Officer » 07:02
08/11/20
08/11
07:02
08/11/20
07:02
BCYC

Bicycle Therapeutics

$15.92 /

+0.09 (+0.57%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, AZN

AstraZeneca

$55.40 /

-0.005 (-0.01%)

, AMGN

Amgen

$238.12 /

-2.45 (-1.02%)

, ADAP

Adaptimmune

$8.28 /

+0.32 (+4.02%)

Bicycle Therapeutics…

Bicycle Therapeutics (BCYC) announced the appointment of Dominic Smethurst, as Chief Medical Officer. Smethurst brings to Bicycle extensive expertise in developing bispecific immuno-oncology agents, as well as toxin conjugate therapeutics for cancer and other serious diseases. Dominic Smethurst has over twenty years of experience working with leading pharmaceutical and biotechnology companies, clinical research institutions, and the UK's National Health Service. He was most recently a medical consultant, advising biopharma companies on clinical development strategies and licensing projects. Prior to that, he served as Chief Medical Officer of Tusk Therapeutics, an immuno-oncology company acquired by Roche (RHHBY), where he oversaw development of antibodies targeting CD25 and CD137, among others. Previously, as Vice President Oncology and Global Therapeutic Area Lead at Icon, a global contract research organization, he executed clinical trials involving numerous novel cancer treatments, including CAR-T therapies. Prior to that, Smethurst held physician leadership roles at AstraZeneca (AZN), Amgen (AMGN) and Adaptimmune (ADAP).

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

BCYC Bicycle Therapeutics
$15.92 /

+0.09 (+0.57%)

AZN AstraZeneca
$55.40 /

-0.005 (-0.01%)

AMGN Amgen
$238.12 /

-2.45 (-1.02%)

ADAP Adaptimmune
$8.28 /

+0.32 (+4.02%)

BCYC Bicycle Therapeutics
$15.92 /

+0.09 (+0.57%)

06/11/20 Oppenheimer
Oppenheimer starts 'revolutionary' Bicycle Therapeutics at Outperform
06/11/20 Oppenheimer
Bicycle Therapeutics initiated with an Outperform at Oppenheimer
04/17/20
Fly Intel: Top five analyst initiations
04/17/20 H.C. Wainwright
Bicycle Therapeutics initiated with a Buy at H.C. Wainwright
RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
AZN AstraZeneca
$55.40 /

-0.005 (-0.01%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
AMGN Amgen
$238.12 /

-2.45 (-1.02%)

07/29/20 Piper Sandler
Piper says AbbVie's atogepant 'may yet emerge as best in class'
07/29/20 SVB Leerink
Amgen price target raised to $261 from $253 at SVB Leerink
07/29/20 Wells Fargo
Amgen price target raised to $247 from $237 at Wells Fargo
07/29/20 RBC Capital
Amgen price target lowered to $223 from $236 at RBC Capital
ADAP Adaptimmune
$8.28 /

+0.32 (+4.02%)

06/01/20 Mizuho
Adaptimmune price target raised to $9 from $3 at Mizuho
05/29/20 JonesTrading
JonesTrading upgrades Adaptimmune to Buy after data alleviates 'key concern'
05/29/20 JonesTrading
Adaptimmune upgraded to Buy from Hold at JonesTrading
05/29/20 Mizuho
Adaptimmune data 'incrementally supportive,' but still early, says Mizuho
RHHBY Roche
$0.00 /

+ (+0.00%)

BCYC Bicycle Therapeutics
$15.92 /

+0.09 (+0.57%)

AZN AstraZeneca
$55.40 /

-0.005 (-0.01%)

AMGN Amgen
$238.12 /

-2.45 (-1.02%)

ADAP Adaptimmune
$8.28 /

+0.32 (+4.02%)

  • 02
    Jun
  • 22
    Jan
RHHBY Roche
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$55.40 /

-0.005 (-0.01%)

AMGN Amgen
$238.12 /

-2.45 (-1.02%)

RHHBY Roche
$0.00 /

+ (+0.00%)

BCYC Bicycle Therapeutics
$15.92 /

+0.09 (+0.57%)

AZN AstraZeneca
$55.40 /

-0.005 (-0.01%)

AMGN Amgen
$238.12 /

-2.45 (-1.02%)

ADAP Adaptimmune
$8.28 /

+0.32 (+4.02%)

AZN AstraZeneca
$55.40 /

-0.005 (-0.01%)

AMGN Amgen
$238.12 /

-2.45 (-1.02%)

ADAP Adaptimmune
$8.28 /

+0.32 (+4.02%)

Saturday
On The Fly
Week in review: How Trump's policies moved stocks » 07:32
08/08/20
08/08
07:32
08/08/20
07:32
TCEHY

Tencent

$0.00 /

+ (+0.00%)

, MSFT

Microsoft

$212.45 /

-3.87 (-1.79%)

, AZN

AstraZeneca

$55.40 /

-0.8 (-1.42%)

, BMY

Bristol-Myers

$61.03 /

-0.27 (-0.44%)

, LLY

Eli Lilly

$152.89 /

+0.01 (+0.01%)

, GSK

GlaxoSmithKline

$40.79 /

-0.185 (-0.45%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, KODK

Eastman Kodak

$14.88 /

-1.195 (-7.43%)

, AA

Alcoa

$14.67 /

-0.22 (-1.48%)

, CENX

Century Aluminum

$10.53 /

-0.06 (-0.57%)

, KALU

Kaiser Aluminum

$66.81 /

+0.49 (+0.74%)

, ARNC

Arconic

$19.94 /

-0.395 (-1.94%)

, FB

Facebook

$268.52 /

+3.295 (+1.24%)

, TWTR

Twitter

$37.14 /

-0.55 (-1.46%)

Catch up on the top…

Open Full Text

ShowHide Related Items >><<
TWTR Twitter
$37.14 /

-0.55 (-1.46%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

KODK Eastman Kodak
$14.88 /

-1.195 (-7.43%)

KALU Kaiser Aluminum
$66.81 /

+0.49 (+0.74%)

GSK GlaxoSmithKline
$40.79 /

-0.185 (-0.45%)

FB Facebook
$268.52 /

+3.295 (+1.24%)

CENX Century Aluminum
$10.53 /

-0.06 (-0.57%)

BMY Bristol-Myers
$61.03 /

-0.27 (-0.44%)

AZN AstraZeneca
$55.40 /

-0.8 (-1.42%)

ARNC Arconic
$19.94 /

-0.395 (-1.94%)

AA Alcoa
$14.67 /

-0.22 (-1.48%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

08/03/20 Morgan Stanley
Sohu.com named a Research Tactical Idea at Morgan Stanley
07/27/20 Barclays
Tencent price target raised to $75 from $63 at Barclays
07/14/20 Citi
Tencent price target raised to HK$649 from HK$541 at Citi
07/08/20 Mizuho
Tencent price target raised to HK$475 from HK$410 at Mizuho
MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

08/07/20 DA Davidson
Datadog price target raised to $80 from $52 at DA Davidson
08/05/20 Morgan Stanley
Morgan Stanley says TikTok US operations could be 'compelling' fit for Microsoft
08/04/20 Wedbush
Wedbush sees 75%-80% chance of Microsoft buying TikTok's U.S. operations
08/04/20 Oppenheimer
TikTok presents 'unique opportunity' for Microsoft, says Oppenheimer
AZN AstraZeneca
$55.40 /

-0.8 (-1.42%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
BMY Bristol-Myers
$61.03 /

-0.27 (-0.44%)

08/06/20 Citi
Investors can refocus on Bristol-Myers story after Eliquis win, says Citi
07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
07/28/20 Raymond James
Bristol-Myers initiated with an Outperform at Raymond James
LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

07/31/20 Barclays
Eli Lilly earnings selloff 'meaningful over-reaction,' says Barclays
07/15/20 H.C. Wainwright
Blueprint Medicines price target raised to $110 from $66 at H.C. Wainwright
07/14/20 Baird
Blueprint Medicines price target raised to $100 from $90 at Baird
07/14/20 Raymond James
Blueprint Medicines price target raised to $106 from $95 at Raymond James
GSK GlaxoSmithKline
$40.79 /

-0.185 (-0.45%)

07/31/20 Barclays
Barclays backs Underweight on GSK after 'challenging' Q2
07/30/20 Roth Capital
Roth Capital bullish on Ideaya as GSK highlights synthetic lethality pipeline
07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
KODK Eastman Kodak
$14.88 /

-1.195 (-7.43%)

AA Alcoa
$14.67 /

-0.22 (-1.48%)

07/16/20 B. Riley FBR
Alcoa price target raised to $11 from $9 at B. Riley FBR
06/16/20
Fly Intel: Top five analyst downgrades
06/16/20 Deutsche Bank
Alcoa downgraded to Hold with $10 price target at Deutsche Bank
06/15/20 Deutsche Bank
Alcoa downgraded to Hold from Buy at Deutsche Bank
CENX Century Aluminum
$10.53 /

-0.06 (-0.57%)

06/25/20 BMO Capital
Century Aluminum downgraded to Market Perform from Outperform at BMO Capital
06/09/20 B. Riley FBR
B. Riley FBR downgrades Contura Energy after liquidity stress test
03/24/20 B. Riley FBR
Century Aluminum downgraded to Neutral from Buy at B. Riley FBR
12/20/19 B. Riley FBR
Alcoa price target lowered to $25 from $28 at B. Riley FBR
KALU Kaiser Aluminum
$66.81 /

+0.49 (+0.74%)

01/16/20 Benchmark
Kaiser Aluminum initiated with a Hold at Benchmark
ARNC Arconic
$19.94 /

-0.395 (-1.94%)

05/20/20
Fly Intel: Top five analyst initiations
05/20/20 Credit Suisse
Arconic initiated with an Outperform at Credit Suisse
04/01/20 Cowen
Howmet Aerospace price target lowered to $17 from $23 at Cowen
03/20/20 Barclays
Arconic downgraded to Equal Weight from Overweight at Barclays
FB Facebook
$268.52 /

+3.295 (+1.24%)

08/10/20 Truist
Trade Desk price target raised to $450 from $250 at Truist
08/10/20 Morgan Stanley
Pinterest upgraded to Overweight on social shopping trend at Morgan Stanley
08/10/20 Mizuho
Facebook price target raised to $315 from $285 at Mizuho
08/05/20 HSBC
HSBC bumps up Facebook target to $195, maintains Reduce rating
TWTR Twitter
$37.14 /

-0.55 (-1.46%)

07/28/20 Morgan Stanley
Morgan Stanley lowers near-term, long-term forecasts for Roku
07/24/20 Truist
Twitter price target raised to $40 from $32 at SunTrust
07/24/20 Argus
Twitter price target raised to $46 from $40 at Argus
07/24/20 Canaccord
Twitter price target raised to $40 from $32 at Canaccord
TWTR Twitter
$37.14 /

-0.55 (-1.46%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

KALU Kaiser Aluminum
$66.81 /

+0.49 (+0.74%)

GSK GlaxoSmithKline
$40.79 /

-0.185 (-0.45%)

FB Facebook
$268.52 /

+3.295 (+1.24%)

CENX Century Aluminum
$10.53 /

-0.06 (-0.57%)

BMY Bristol-Myers
$61.03 /

-0.27 (-0.44%)

AZN AstraZeneca
$55.40 /

-0.8 (-1.42%)

ARNC Arconic
$19.94 /

-0.395 (-1.94%)

AA Alcoa
$14.67 /

-0.22 (-1.48%)

TWTR Twitter
$37.14 /

-0.55 (-1.46%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

KODK Eastman Kodak
$14.88 /

-1.195 (-7.43%)

GSK GlaxoSmithKline
$40.79 /

-0.185 (-0.45%)

FB Facebook
$268.52 /

+3.295 (+1.24%)

BMY Bristol-Myers
$61.03 /

-0.27 (-0.44%)

AZN AstraZeneca
$55.40 /

-0.8 (-1.42%)

AA Alcoa
$14.67 /

-0.22 (-1.48%)

TWTR Twitter
$37.14 /

-0.55 (-1.46%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

KODK Eastman Kodak
$14.88 /

-1.195 (-7.43%)

GSK GlaxoSmithKline
$40.79 /

-0.185 (-0.45%)

FB Facebook
$268.52 /

+3.295 (+1.24%)

BMY Bristol-Myers
$61.03 /

-0.27 (-0.44%)

AZN AstraZeneca
$55.40 /

-0.8 (-1.42%)

ARNC Arconic
$19.94 /

-0.395 (-1.94%)

AA Alcoa
$14.67 /

-0.22 (-1.48%)

TWTR Twitter
$37.14 /

-0.55 (-1.46%)

MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

LLY Eli Lilly
$152.89 /

+0.01 (+0.01%)

KODK Eastman Kodak
$14.88 /

-1.195 (-7.43%)

GSK GlaxoSmithKline
$40.79 /

-0.185 (-0.45%)

FB Facebook
$268.52 /

+3.295 (+1.24%)

BMY Bristol-Myers
$61.03 /

-0.27 (-0.44%)

AZN AstraZeneca
$55.40 /

-0.8 (-1.42%)

ARNC Arconic
$19.94 /

-0.395 (-1.94%)

AA Alcoa
$14.67 /

-0.22 (-1.48%)

MSFT Microsoft
$212.45 /

-3.87 (-1.79%)

Over a week ago
Earnings
FibroGen sees ending year with $720M-$730M in cash, cash equivalents » 16:07
08/06/20
08/06
16:07
08/06/20
16:07
FGEN

FibroGen

$41.39 /

-1.25 (-2.93%)

Based on the…

Based on the company's latest forecast, it reiterates its year-end 2020 estimate to be in the range of $720M-$730M in cash, cash equivalents, restricted time deposits, investments, and receivables.

ShowHide Related Items >><<
FGEN FibroGen
$41.39 /

-1.25 (-2.93%)

FGEN FibroGen
$41.39 /

-1.25 (-2.93%)

07/10/20 Stifel
FibroGen transferred with Buy rating, $71 target at Stifel
05/06/20 RBC Capital
Akebia price target raised to $12 from $8 at RBC Capital
05/05/20 Piper Sandler
Piper Sandler remains a buyer of Akebia following Phase 3 INNO2VATE data
05/05/20 Piper Sandler
Piper says efficacy, safety of FibroGen, Akebia drugs 'quite similar' in DD-CKD
FGEN FibroGen
$41.39 /

-1.25 (-2.93%)

FGEN FibroGen
$41.39 /

-1.25 (-2.93%)

Earnings
FibroGen reports Q2 EPS (95c), consensus (64c) » 16:06
08/06/20
08/06
16:06
08/06/20
16:06
FGEN

FibroGen

$41.39 /

-1.25 (-2.93%)

Reports Q2 revenue…

Reports Q2 revenue $42.9M, consensus $33.8M. At June 30, FibroGen had $716.0M in cash, cash equivalents, restricted time deposits, investments, and receivables.

ShowHide Related Items >><<
FGEN FibroGen
$41.39 /

-1.25 (-2.93%)

FGEN FibroGen
$41.39 /

-1.25 (-2.93%)

07/10/20 Stifel
FibroGen transferred with Buy rating, $71 target at Stifel
05/06/20 RBC Capital
Akebia price target raised to $12 from $8 at RBC Capital
05/05/20 Piper Sandler
Piper Sandler remains a buyer of Akebia following Phase 3 INNO2VATE data
05/05/20 Piper Sandler
Piper says efficacy, safety of FibroGen, Akebia drugs 'quite similar' in DD-CKD
FGEN FibroGen
$41.39 /

-1.25 (-2.93%)

FGEN FibroGen
$41.39 /

-1.25 (-2.93%)

Periodicals
Trump to order government to buy certain drugs from U.S., USA Today says » 10:12
08/06/20
08/06
10:12
08/06/20
10:12
JNJ

Johnson & Johnson

$148.29 /

-0.1 (-0.07%)

, LLY

Eli Lilly

$154.75 /

+0.36 (+0.23%)

, MRK

Merck

$81.48 /

-0.13 (-0.16%)

, PFE

Pfizer

$38.73 /

+0.28 (+0.73%)

, SNY

Sanofi

$51.41 /

-0.27 (-0.52%)

, AZN

AstraZeneca

$56.22 /

+0.3 (+0.54%)

, GSK

GlaxoSmithKline

$41.04 /

-0.17 (-0.41%)

, NVS

Novartis

$83.51 /

+0.07 (+0.08%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$61.67 /

+1.98 (+3.32%)

President Donald Trump…

President Donald Trump will sign an executive order mandating the federal government to buy certain drugs from U.S. manufacturers rather than foreign companies, USA Today's Michael Collins reports, citing officials. The order, which will be signed at Whirlpool's (WHR) manufacturing facility in Ohio, requires the government to develop a list of "essential" medicines and purchase them as well as other medical supplies from the U.S. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Reference Link

ShowHide Related Items >><<
SNY Sanofi
$51.41 /

-0.27 (-0.52%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.73 /

+0.28 (+0.73%)

NVS Novartis
$83.51 /

+0.07 (+0.08%)

MRK Merck
$81.48 /

-0.13 (-0.16%)

LLY Eli Lilly
$154.75 /

+0.36 (+0.23%)

JNJ Johnson & Johnson
$148.29 /

-0.1 (-0.07%)

GSK GlaxoSmithKline
$41.04 /

-0.17 (-0.41%)

BMY Bristol-Myers
$61.67 /

+1.98 (+3.32%)

AZN AstraZeneca
$56.22 /

+0.3 (+0.54%)

JNJ Johnson & Johnson
$148.29 /

-0.1 (-0.07%)

07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/29/20 Laidlaw
Curis initiated with a Buy at Laidlaw
07/17/20 Goldman Sachs
J&J valuation discount to S&P 500 'too wide,' says Goldman Sachs
07/17/20 Citi
Johnson & Johnson price target raised to $170 from $165 at Citi
LLY Eli Lilly
$154.75 /

+0.36 (+0.23%)

07/31/20 Barclays
Eli Lilly earnings selloff 'meaningful over-reaction,' says Barclays
07/15/20 H.C. Wainwright
Blueprint Medicines price target raised to $110 from $66 at H.C. Wainwright
07/14/20 Baird
Blueprint Medicines price target raised to $100 from $90 at Baird
07/14/20 Raymond James
Blueprint Medicines price target raised to $106 from $95 at Raymond James
MRK Merck
$81.48 /

-0.13 (-0.16%)

08/04/20 Piper Sandler
Merck deal sparks interest in GLP-1:glucagon agonists, says Piper Sandler
08/03/20
Fly Intel: Top five analyst upgrades
08/03/20 Goldman Sachs
Merck upgraded to Buy from Neutral at Goldman Sachs
PFE Pfizer
$38.73 /

+0.28 (+0.73%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
SNY Sanofi
$51.41 /

-0.27 (-0.52%)

07/31/20 JPMorgan
Sanofi price target raised to EUR 106 from EUR 103 at JPMorgan
07/20/20 BMO Capital
Immunic initiated with an Outperform at BMO Capital
07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
AZN AstraZeneca
$56.22 /

+0.3 (+0.54%)

07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
GSK GlaxoSmithKline
$41.04 /

-0.17 (-0.41%)

07/31/20 Barclays
Barclays backs Underweight on GSK after 'challenging' Q2
07/30/20 Roth Capital
Roth Capital bullish on Ideaya as GSK highlights synthetic lethality pipeline
07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
NVS Novartis
$83.51 /

+0.07 (+0.08%)

07/28/20 Morgan Stanley
Novartis price target raised to CHF 93 from CHF 91 at Morgan Stanley
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
BMY Bristol-Myers
$61.67 /

+1.98 (+3.32%)

08/06/20 Citi
Investors can refocus on Bristol-Myers story after Eliquis win, says Citi
07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
07/28/20 Raymond James
Bristol-Myers initiated with an Outperform at Raymond James
SNY Sanofi
$51.41 /

-0.27 (-0.52%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.73 /

+0.28 (+0.73%)

NVS Novartis
$83.51 /

+0.07 (+0.08%)

MRK Merck
$81.48 /

-0.13 (-0.16%)

LLY Eli Lilly
$154.75 /

+0.36 (+0.23%)

JNJ Johnson & Johnson
$148.29 /

-0.1 (-0.07%)

GSK GlaxoSmithKline
$41.04 /

-0.17 (-0.41%)

BMY Bristol-Myers
$61.67 /

+1.98 (+3.32%)

AZN AstraZeneca
$56.22 /

+0.3 (+0.54%)

SNY Sanofi
$51.41 /

-0.27 (-0.52%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.73 /

+0.28 (+0.73%)

NVS Novartis
$83.51 /

+0.07 (+0.08%)

MRK Merck
$81.48 /

-0.13 (-0.16%)

LLY Eli Lilly
$154.75 /

+0.36 (+0.23%)

JNJ Johnson & Johnson
$148.29 /

-0.1 (-0.07%)

GSK GlaxoSmithKline
$41.04 /

-0.17 (-0.41%)

AZN AstraZeneca
$56.22 /

+0.3 (+0.54%)

SNY Sanofi
$51.41 /

-0.27 (-0.52%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NVS Novartis
$83.51 /

+0.07 (+0.08%)

MRK Merck
$81.48 /

-0.13 (-0.16%)

LLY Eli Lilly
$154.75 /

+0.36 (+0.23%)

JNJ Johnson & Johnson
$148.29 /

-0.1 (-0.07%)

GSK GlaxoSmithKline
$41.04 /

-0.17 (-0.41%)

BMY Bristol-Myers
$61.67 /

+1.98 (+3.32%)

AZN AstraZeneca
$56.22 /

+0.3 (+0.54%)

SNY Sanofi
$51.41 /

-0.27 (-0.52%)

PFE Pfizer
$38.73 /

+0.28 (+0.73%)

NVS Novartis
$83.51 /

+0.07 (+0.08%)

MRK Merck
$81.48 /

-0.13 (-0.16%)

LLY Eli Lilly
$154.75 /

+0.36 (+0.23%)

JNJ Johnson & Johnson
$148.29 /

-0.1 (-0.07%)

GSK GlaxoSmithKline
$41.04 /

-0.17 (-0.41%)

BMY Bristol-Myers
$61.67 /

+1.98 (+3.32%)

AZN AstraZeneca
$56.22 /

+0.3 (+0.54%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.